Gilead renews IT contract with Cognizant in bid to more quickly bring drugs to market
Gilead is expanding and renewing an IT contract with Cognizant that is now worth up to $800 million over five years.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
